Cutaneous melanoma

Principles of Molecular Medicine

Volumn , Issue , 2006, Pages 757-759

  Moira, R Jackson ^a   Stephen, P Sugrue ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

CDKN2A; E cadherin; epidermis; Melanocyte; melanoma; N cadherin; radial growth phase; UV radiation; vasculogenic mimicry; vertical growth phase

Indexed keywords

EID: 84891432633     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-963-9_77     Document Type: Chapter

References (89)

1. Baldi A, Santini D, Battista T, et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001;83(3):364-372.
2. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001;14(2):78-85.
3. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003;22(20): 3081-3086.
4. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003;22(20):3063-3069.
5. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94(12):894-903.
6. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406 (6795):536-540.
7. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11(21):2822-2834.
8. Ciolczyk-Wierzbicka D, Gil D, Hoja-Lukowicz D, Litynska A, Laidler P. Carbohydrate moieties of N-cadherin from human melanoma cell lines. Acta Biochim Pol 2002;49(4):991-998.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-954.
10. Degen WG, van Kempen LC, Gijzen EG, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 1998;152(3):805-813.
11. Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, van den Oord JJ. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod Pathol 2002;15(4):454-461.
12. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63(14):3883-3885.
13. Dupin E, Le Douarin NM. Development of melanocyte precursors from the vertebrate neural crest. Oncogene 2003;22(20):3016-3023.
14. Dupin E, Real C, Glavieux-Pardanaud C, Vaigot P, Le Douarin NM. Reversal of developmental restrictions in neural crest lineages: Transition from Schwann cells to glial-melanocytic precursors in vitro. Proc Natl Acad Sci USA 2003;100(9):5229-5233.
15. Ferrier CM, van Muijen GN, Ruiter DJ. Proteases in cutaneous melanoma. Ann Med 1998;30(5):431-442.
16. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156(2):361-381.
17. Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001;13(2):117-123.
18. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000;13(1):4-14.
19. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003; 22(20):3053-3062.
20. Heikkila P, Teronen O, Moilanen M. Bisphosphonates inhibit stromelysin- 1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002;13(3):245-254.
21. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene 2003;22(20):3070-3075.
22. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3(6):411-421.
23. Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001;98(14): 8018-8023.
24. Herlyn M, Berking C, Li G, Satyamoorthy K. Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Res 2000;10(4):303-312.
25. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001;1(2):142-150.
26. Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001;61(8):3250-3255.
27. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002;70(9-10): 522-536.
28. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000; 156(5):1515-1525.
29. Ichihashi M, Ueda M, Budiyanto A, et al. UV-induced skin damage. Toxicology 2003;189(1-2):21-39.
30. Jean D, Gershenwald JE, Huang S, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273(26):16,501-16,508.
31. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003;22(20):3099-3112.
32. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18(3):345-357.
33. Kamada S, Shimono A, Shinto Y, et al. BCL-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 1995;55(2):354-359.
34. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA 2003;100(3): 1221-1225.
35. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413(6851):83-86.
36. Kurschat P, Mauch C. Mechanisms of metastasis. Clin Exp Dermatol 2000;25(6):482-489.
37. Li G, Ho VC. p53-dependent DNA repair and apoptosis respond differently to high- and low-dose ultraviolet radiation. Br J Dermatol 1998;139(1):3-10.
38. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001;61(9):3819-3825.
39. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003;22(20):3162-3171.
40. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20(56):8125-8135.
41. Longo N,Yanez-Mo M,Mittelbrunn M, et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001;98(13):3717-3726.
42. Luca MR, Bar-Eli M. Molecular changes in human melanoma metastasis. Histol Histopathol 1998;13(4):1225-1231.
43. MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. 'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 1999;80(3-4):504-512.
44. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155(3):739-752.
45. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1(5):459-465.
46. McGill GG, Horstmann M, Widlund HR, et al. BCL-2 regulation by the melanocyte master regulator MITF modulates lineage survival and melanoma cell viability. Cell 2002;109(6):707-718.
47. Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression. Front Biosci 1998;3:D1005-D1010.
48. Mollaaghababa R, Pavan WJ. The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia. Oncogene 2003;22(20):3024-3034.
49. Nakayama K, Negishi I, Negishi I, Kuida K, Sawa H, Loh DY. Targeted disruption of BCL-2 alpha beta in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 1994;91(9):3700- 3704.
50. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92(10):3694-3700.
51. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 2003;20(3):251-263.
52. Pavey S, Gabrielli B. Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res 2002;62(3):875-880.
53. Pavey S, Russell T, Gabrielli B. G2 phase cell cycle arrest in human skin following UV irradiation. Oncogene 2001;20(43):6103-6110.
54. Perez-Moreno MA, Locascio A, Rodrigo I, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 2001;276(29):27,424-27,431.
55. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33(1):19-20.
56. Pollock PM, Hayward N. Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. Melanoma Res 2002;12(2):183-186.
57. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22(20):3087-3091.
58. Poser I, Dominguez D, de Herreros AG,Varnai A, Buettner R, Bosserhoff AK. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 2001;276(27):24, 661-24,666.
59. Ramjeesingh R, Leung R, Siu CH. Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J 2003;17(10):1292-1294.
60. Randerson-Moor JA, Harland M,Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001;10(1):55-62.
61. Reifenberger J, Knobbe CB, Wolter M, et al. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 2002;100(5):549-556.
62. Reinke V, Lozano G. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res 1997;148(2):115-122.
63. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene 2001;20(39): 5543-5547.
64. Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol 1999;52(3):151-157.
65. Sandig M, Voura EB, Kalnins VI, Siu CH. Role of cadherins in the transendothelial migration of melanoma cells in culture. Cell Motil Cytoskeleton 1997;38(4):351-364.
66. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002;62(11):3200-3206.
67. Seftor EA, Meltzer PS, Schatteman GC, et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002;44(1):17-27.
68. Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev 1999;18(3):359-375.
69. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001;61(17): 6322-6327.
70. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003;22(20):3092-3098.
71. Simonetti O, Lucarini G, Brancorsini D, et al. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 2002;95(9):1963-1970.
72. Slattery MJ, Dong C. Neutrophils influence melanoma adhesion and migration under flow conditions. Int J Cancer 2003;106(5):713-722.
73. Slominski A,Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch Pathol Lab Med 2001;125(10):1295-1306.
74. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104(5):527-532.
75. Soufir N,Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7(2):209-216.
76. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003;22(20):3172-3179.
77. Suzuki I, Im S, Tada A, et al. Participation of the melanocortin-1 receptor in the UV control of pigmentation. J Investig Dermatol Symp Proc 1999;4(1):29-34.
78. Takeda K,Yasumoto K, Takada R, et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J Biol Chem 2000;275(19):14,013-14,016.
79. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003;22(20):3130-3137.
80. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22(20):3042-3052.
81. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003;100(5):2645-2650.
82. Voura EB, Sandig M, Siu CH. Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech 1998;43(3):265-275.
83. Walker GJ, Hayward NK. Pathways to melanoma development: lessons from the mouse. J Invest Dermatol 2002;119(4):783-792.
84. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1(3):279-288.
85. Widlund HR, Horstmann MA, Price ER, et al. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmiaassociated transcription factor. J Cell Biol 2002;158(6):1079-1087.
86. Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001;155(4):505-510.
87. Yang FC, Merlino G, Chin L. Genetic dissection of melanoma pathways in the mouse. Semin Cancer Biol 2001;11(3):261-268.
88. Yoshimura M, Ihara Y, Matsuzawa Y, Taniguchi N. Aberrant glycosylation of E-cadherin enhances cell-cellbinding to suppress metastasis. J Biol Chem 1996;271(23):13,811-13,815.
89. Zuo L,Weger J,Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12(1): 97-99.